ICICI Securities has upgraded Cipla to a BUY rating with a revised target price of Rs 1,550, implying a potential upside of nearly 19% from the current market price of Rs 1,306. The discontinuation of key products and loss of exclusivity had cast a shadow over growth prospects, but new launches such as gOfev and gVentolin are poised to stabilize revenues. Combined with robust domestic performance and strategic in-licensing deals, the company is rebuilding its growth trajectory. With improving earnings visibility, strong cash reserves, and attractive valuations at 19.2x FY28E EPS, ICICI Securities sees meaningful upside ahead.

US Business Recovery: Launch Momentum Offsets Legacy Weakness

New product approvals are emerging as critical growth drivers. Cipla recently secured USFDA approvals for gVentolin (albuterol inhaler) and gOfev (nintedanib), two high-value products expected to collectively generate approximately USD 100 million annually.

The gVentolin launch is particularly strategic, targeting a market size of nearly USD 490 million in the U.S., reinforcing Cipla’s leadership in respiratory therapies. These launches come at a time when the company is navigating revenue pressures from the discontinuation of Lanreotide and the erosion of exclusivity in gRevlimid.

Forward visibility improves with a strong pipeline. Management expects multiple upcoming approvals, including gAdvair and other respiratory assets, which could further accelerate recovery in the U.S. market.

Pipeline Strength: Multi-Year Growth Engine in Place

Cipla’s pipeline depth remains one of its strongest competitive advantages. The company is preparing to launch 4–5 high-value products over FY27, including respiratory drugs and peptide-based therapies.

Below is a snapshot of key pipeline opportunities:

India Business: A Stable Anchor Driving Consistent Growth

Domestic operations continue to deliver resilient performance. Cipla’s India business is expected to contribute approximately 44% of total revenue in FY26, supported by its strong branded formulations portfolio.

Recent strategic initiatives include:

Acquisition of Inzpera Healthsciences to expand pediatric and wellness segments
In-licensing of GLP-1 therapy (Yurpeak) from Eli Lilly
Partnership with Pfizer for established brands like Corex and Dolonex

Growth outlook remains robust. The India segment is projected to grow at a CAGR of 8.9% between FY26 and FY28, providing a steady earnings base amid global volatility.

Financial Trajectory: Gradual Margin Recovery Ahead

Cipla’s financial performance reflects a near-term dip followed by recovery. EBITDA margins are expected to contract in FY26 but gradually improve thereafter as new launches scale up.

Growth outlook remains intact. Cipla is expected to deliver:

Revenue CAGR: ~10.3% (FY25–FY28)
EBITDA CAGR: ~12.9%
EPS growth: accelerating to 16.6% in FY28

Valuation Case: Attractive Entry at Current Levels

The stock is trading at compelling valuations relative to its growth potential. At current levels, Cipla trades at:

22.4x FY27E EPS
19.2x FY28E EPS
EV/EBITDA of 11.9x FY28E

A sum-of-the-parts valuation suggests significant underlying value:

Strategic Priorities Under New Leadership

Execution will be key under the new CEO, Achin Gupta. Immediate priorities include:

Accelerating U.S. product launches
Improving margins in South Africa operations
Expanding presence in emerging markets and Europe
Strengthening regulatory compliance across manufacturing facilities

Risk Factors: What Could Derail the Thesis

Investors should remain mindful of key risks:

Intensifying competition in niche generic segments
Delays in regulatory approvals, particularly at the Pithampur facility
Continued pricing pressure in the U.S. generics market

Additionally, the USFDA inspection summary on page 3 indicates ongoing regulatory observations at certain facilities, which require close monitoring.

Stock Levels and Investment Strategy

Current Price (CMP): Rs 1,306
Target Price: Rs 1,550
Upside Potential: ~19%

Technical and Investment Levels:

Immediate Support: Rs 1,200 – Rs 1,220
Strong Support Zone: Rs 1,150
Resistance Levels: Rs 1,400 / Rs 1,550

Investment View: Accumulate on dips. The risk-reward profile appears favorable with strong downside protection from domestic operations and cash reserves.

Bottomline: Re-rating Opportunity Emerging

Cipla stands at a pivotal juncture where execution on its pipeline and recovery in U.S. revenues could unlock a meaningful re-rating. The combination of resilient domestic growth, improving global outlook, and attractive valuations creates a compelling investment case. While near-term challenges persist, the medium-term trajectory appears firmly constructive, making Cipla a strong candidate for portfolio accumulation.